Maximizing the Benefit of CAR T-Cell Therapy in Lymphoma and Multiple Myeloma
Saved in:
| Main Author: | Federico Simonetta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2022.13.078 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR‐T cells in the treatment of multiple myeloma: an encouraging cell therapy
by: Tong Yu, et al.
Published: (2025-02-01) -
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
by: Mahmoud R. Gaballa, et al.
Published: (2025-03-01) -
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025-06-01) -
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01) -
Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
by: Liya Wei, et al.
Published: (2025-06-01)